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MUTYH, an adenine DNA glycosylase, mediates p53 tumor
suppression via PARP-dependent cell death
S Oka1,2, J Leon1, D Tsuchimoto1,2, K Sakumi1,2 and Y Nakabeppu1,2
p53-regulated caspase-independent cell death has been implicated in suppression of tumorigenesis, however, the regulating
mechanisms are poorly understood. We previously reported that 8-oxoguanine (8-oxoG) accumulation in nuclear DNA (nDNA) and
mitochondrial DNA triggers two distinct caspase-independent cell death through buildup of single-strand DNA breaks by MutY
homolog (MUTYH), an adenine DNA glycosylase. One pathway depends on poly-ADP-ribose polymerase (PARP) and the other
depends on calpains. Deficiency of MUTYH causes MUTYH-associated familial adenomatous polyposis. MUTYH thereby suppresses
tumorigenesis not only by avoiding mutagenesis, but also by inducing cell death. Here, we identified the functional p53-binding
site in the human MUTYH gene and demonstrated that MUTYH is transcriptionally regulated by p53, especially in the p53/DNA
mismatch repair enzyme, MLH1-proficient colorectal cancer-derived HCT116+Chr3 cells. MUTYH-small interfering RNA, an inhibitor
for p53 or PARP suppressed cell death without an additive effect, thus revealing that MUTYH is a potential mediator of p53 tumor
suppression, which is known to be upregulated by MLH1. Moreover, we found that the p53-proficient, mismatch repair protein,
MLH1-proficient colorectal cancer cell line express substantial levels of MUTYH in nuclei but not in mitochondria, suggesting that 8-
oxoG accumulation in nDNA triggers MLH1/PARP-dependent cell death. These results provide new insights on the molecular
mechanism of tumorigenesis and potential new strategies for cancer therapies.
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INTRODUCTION
8-Oxoguanine (8-oxoG) is one of the major oxidative base lesions
in DNA or nucleotides1 and is highly mutagenic because it can pair
with adenine as well as cytosine.2 Studies on DNA repair
mechanisms directed against 8-oxoG revealed that organisms
are equipped with elaborate means of error avoidance.3,4
In mammals, 8-oxoG DNA glycosylase-1 (OGG1) excises 8-oxoG
paired with cytosine in DNA, whereas the MutY homolog (MUTYH)
removes adenine misincorporated opposite 8-oxoG in template
DNA.4,5 These enzymes have major roles in suppressing sponta-
neous mutagenesis initiated by 8-oxoG. Mutant mice lacking one
of these genes exhibit an increased spontaneous mutation rate
and an increased susceptibility to carcinogenesis.6,7
The human MUTYH gene is located on the short arm of
chromosome 1, spans 11.2 kb and contains 16 exons. In human
cells, transcription of MUTYH is initiated from three distinct exon 1
sequences, thus producing three types of primary transcripts,
namely α, β and γ (Figure 1a). From these three primary
transcripts, 415 transcripts are generated by alternative splicing
at exon 1 and exon 3. Type α3 MUTYH mRNA is a major MUTYH
transcript and encodes the most abundantly expressed mitochon-
drial MUTYH.8–10 In contrast, MUTYH encoded by type β3, β5 or γ3
mRNA is the most abundant nuclear isoform.
The human MUTYH gene has been reported as the causative
gene of autosomal recessive familial adenomatous polyposis
without a germline APC mutation and is now referred to as
MUTYH-associated polyposis.11–13 Furthermore, MUTYH-null mice
exhibited an increase in the spontaneous incident rate of
adenoma/adenocarcinoma in the small intestine and colon,
and the rate increased markedly following oxidative stress.6
We previously reported that accumulation of 8-oxoG in nuclear
DNA (nDNA) and mitochondrial DNA (mtDNA) independently
triggers two distinct cell death pathways through a common
signal of buildup of single-strand DNA breaks (SSBs). During
replication, adenine can be inserted opposite to 8-oxoG that is
accumulated in DNA, thereby forming a considerable number of
A:8-oxoG pairs in DNA. MUTYH excises adenines that are opposite
to 8-oxoG through its adenine DNA glycosylase activity, and forms
abasic sites that are converted to SSBs by apurinic/apyrimidinic
(AP) endonucleases. The buildup of SSBs in nDNA causes poly-
ADP-ribose polymerase (PARP)-dependent nuclear translocation of
apoptosis-inducing factor, while that in mtDNA causes mtDNA
depletion and calpain activation, thereby executing caspase-
independent cell death.14 MUTYH suppresses tumorigenesis not
only by avoiding mutagenesis, but also by inducing cell death.9
Loss of p53 function has been extensively reported in many
forms of cancer.15,16 It was reported that the transcriptional factor
p53 has a crucial role in the DNA repair system by regulating
transcription of the human OGG1 gene.17 In this study, we
demonstrate that the human MUTYH gene is a transcriptional
target of p53 and thus propose that MUTYH is a potential
mediator of p53 tumor suppression by inducing death of
premutagenic cells generated under oxidative conditions.
RESULTS
p53 regulates expression levels of MUTYH mRNA and protein
To determine whether basal level expression of MUTYH mRNA is
dependent on p53, we first compared levels of mRNAs encoding
the nuclear form of MUTYH β, the mitochondrial form of MUTYH α
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and p21 as a target of p53 transcription in H1299, HCT116 and
HCT116+Chr3 human cancer cell lines. HCT116 is a p53-proficient,
DNA mismatch repair enzyme, MLH1-deficient human colorectal
cancer cell line,18–20 and H1299 is a p53-deficient MLH1-proficient
human lung small cell carcinoma cell line.21 Moreover, to exclude
the influence of MLH1 deficiency, we used HCT116+Chr3 cells
expressing functional MLH1 by transferring human chromosome 3
into HCT116 cells.22
As shown in the left panel in Figure 1b, real-time quantitative
reverse transcriptase-PCR (RT–PCR) analysis revealed that relative
levels of p21 mRNA in p53-proficient HCT116 or HCT116+Chr3
cells were higher than in p53-deficient H1299 cells. As over-
expression of MLH1 induces p53-Ser15 phosphorylation, which
regulates transcriptional activity in HCT116 cells treated with
radiomimetic chemical neocarzinostatin,23 elevated p21 mRNA
levels in HCT116+Chr3 cells is considered an MLH1-dependent
increase of p53-mediated transactivation.
Levels of mRNAs encoding the nuclear and mitochondrial forms
of MUTYH were increased in HCT116+Chr3 cells when compared
with H1299 cells (Figure 1b, middle and right panel). We further
examined whether the expression of MUTYH mRNAs was induced
by the transfection of the wild-type p53 expression plasmid in
p53-deficient H1299 cells. The level of p21 and MUTYH β mRNA
was markedly increased 24 h after transfection with the p53
expression plasmid in a dose-dependent manner (Figure 1c).
H1299 cells transfected with 100 ng, and to a lesser extent 200 ng,
p53 expression plasmid exhibited elevated levels of the mito-
chondrial form of MUTYH α mRNA.
Next, we confirmed that expression levels of OGG1 protein were
dependent on p53 by western blot analysis. The band intensity
corresponding to OGG1 was low in p53-deficient H1299 cells
compared with p53-proficient HCT116 cells (Figure 2a). The band
intensity in HCT116 cells decreased in the presence of the
chemical inhibitor of p53 pifithrin-α (PFTα). As well as OGG1,
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Figure 1. p53 regulates expression levels of MUTYH mRNA. (a) Genomic organization of MUTYH. The MUTYH gene produces three types of
transcripts, α, β and γ. (b) Expression levels of MUTYH and p21 mRNA in p53-deficient and -proficient cells. MUTYH and p21 mRNA levels in
HCT116 cells (p53-proficient and MLH1-deficient), HCT116+Chr3 cells (p53 and MLH1-proficient) and H1299 cells (p53-deficient and
MLH1-proficient) were quantified by real-time RT–PCR. Each value was normalized for 18S ribosomal RNA level, and was shown as fold
increase relative to H1299 cells. Analysis of variance (ANOVA), Po0.0001. P-values with Dunnett’s method are shown. *P= 0.0369, **Po0.0001
vs H1299 (left panel). *P= 0.0051, **Po0.0001 vs H1299 (middle panel). *P= 0.0002, **Po0.0001 vs H1299 (right panel). (c) Expression levels
of MUTYH and p21 mRNA levels in H1299 cells 24 h after transfection with increasing amounts of a wild-type p53 expression plasmid.
Each value was normalized for 18S ribosomal RNA level, and was shown as fold increase relative to cells without plasmid (0 ng). ANOVA,
Po0.0434. P-values with Dunnett’s method are shown. *P= 0.219, **P= 0.0017, ***Po0.0001 vs 0 ng (left panel). *P= 0.0468, **P= 0.0277
vs 0 ng (middle panel). *P= 0.0016 vs 0 ng (right panel). Results as shown in panels (b) and (c) are from three independent experiments.
Mean± s.d.
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the band intensity of the 53-kDa polypeptide corresponding to
the nuclear isoform of MUTYH encoded by MUTYH β mRNA in
p53-deficient H1299 cells was markedly lower than that in p53-
proficient HCT116 cell (Figure 2b, left panel). PFTα treatment
decreased the band intensity corresponding to the 53-kDa MUTYH
protein β in HCT116 cells. In HCT116 cells, the 57-kDa band
corresponding to the mitochondrial form of MUTYH reported in
the human T-cell lymphoblast-like Jurkat cell line was not
detected.24 Inactivation of p53 in HCT116 cells by transfection
with a dominant-negative p53 expression vector also decreased
the band intensity of the 53-kDa MUTYH protein β (Figure 2b,
middle and right panels). An immunofluorescent signal for MUTYH
in HCT116 cells was more intense than that in H1299 cells and was
observed to mainly colocalize with 4’, 6-diamino-2-phenylindole
75
50
KDa
 75 
50 
KDa
H
CT
11
6 
H
12
99
 
DAPI MUTYH/HSP60HSP60 Merged MUTYH
50
75
37
KDa
H1299 PFT
PFT
-Actin
-Actin
HCT116 
Staining 
37
50
25
KDa
H1299-
HCT116a
b
c
d
HCT116 
 50 
75 
 37 
KDa
p53mt135 - +
p53mt135 - +
0.0
0.2
0.4
0.6
0.8
1.0
1.2
R
el
at
iv
e 
le
ve
l o
f
p2
1 
m
RN
A 
*
+
- +
Figure 2. p53 regulates expression of MUTYH protein in various cancer cell lines. (a) Expression of OGG1 protein in H1299 cells and HCT116
cells with or without the chemical p53 inhibitor PFTα. Western blot analysis was performed using anti-HCD. Arrowhead indicates the
polypeptide corresponding to OGG1. Staining, GelCode Blue Stain. (b) p53-dependent expression of MUTYH protein. Expression of MUTYH
protein in H1299 cells and HCT116 cells treated with (+) or without (− ) PFTα (left panel), and in HCT116 cells transfected with (+) or without
(− ) the dominant-negative p53 expression vector (pCMV-p53mt135) (middle panel). Western blot analysis was performed using anti-MUTYH.
Arrowhead indicates the polypeptide corresponding to the nuclear isoform encoded by MUTYH β mRNA. Decreased expression of p21 mRNA
in HCT116 cells transfected with pCMV-p53mt135 (right panel). *P= 0.0003. P-value with Student’s t-test is shown. Results from three
independent transfection experiments are presented. Mean± s.d. (c) Expression and intracellular localization of MUTYH. Nuclei were stained
with 4’, 6-diamino-2-phenylindole (DAPI). HSP60 was used as a mitochondrial marker. Bar, 20 μm. (d) MUTYH protein expression in human
cancer cell lines with impaired p53 function (HeLa MR and HeLa S3, upper panel) and human colon cancer cell lines with p53 mutation (DLD-1
and HT29, lower panel).
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staining, a nuclear marker, but not the mitochondrial protein
HSP60 (Figure 2c). These results suggest that expression levels of
the nuclear isoform of MUTYH encoded by MUTYHβ mRNA, are
positively regulated by p53 in the human colorectal cancer
cell line.
Expression levels of MUTYH protein in human cancer cell lines
with varying p53 statuses
We next examined MUTYH protein expression levels in human
cancer cell lines with varying p53 statuses. HeLa MR and HeLaS3
cells, which are human epithelioid cervical carcinoma cell lines,
have impaired p53 function because of the expression of the
human papilloma virus E6 gene product.25 In HeLa cells, protein
expression of the 53-kDa nuclear isoform of MUTYH was lower
than that in p53-proficient HCT116 cells (Figure 2d, upper panel).
Moreover, in the human colon cancer cell lines with p53
mutations, DLD-1 cells with S241F and HT29 cells with R273H,26
exhibited a clear reduction in expression levels when compared
with HCT116 cells (Figure 2d, lower panel).
p53 responsive elements reside within the human MUTYH gene
To identify potential p53 responsive elements (p53REs), we
searched the genomic sequence of the human MUTYH gene and
sequences 1.5 kb upstream using the consensus DNA sequence
element for p53 binding, RRRCWWGYYY as a tandem repeat or
YCTYCWAGR, and detected the five potential p53 response
elements, p53RE1 in the 5′ upstream region of the MUTYH gene,
RE2/3 and RE4/5 in intron 1 (Figure 3a).27 As p53 is required to
directly bind to p53REs to activate the transcription of its target,
we next performed chromatin immunoprecipitation (ChIP) analy-
sis using p53-deficient, MLH1-proficient H1299, p53-proficient,
MLH1-proficient HCT116+Chr3 or p53-proficient, MLH1-deficient
HCT116 cells (Figure 3b). The co-precipitated DNA with p53 was
subjected to genomic PCR using primers specific for p53RE in p21
as a positive control for p53 binding or primers specific to each of
the potential p53REs. As a result, RE4/5 was found to be associated
with p53 in HCT116+Chr3 or HCT116 cells, implicating these sites
as the p53 response element. Next, to confirm whether these sites
were the functional responsive element, we constructed pGL3-
promoter luciferase reporters containing p53RE1, p53RE4 or
p53RE5. The luciferase activity in cells transfected with the
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Figure 3. Identification of the functional p53REs residing in the human MUTYH gene. (a) Potential p53 response elements (p53REs) in the
human MUTYH gene are indicated. Numbers in parentheses indicate nucleotide positions relative to the transcriptional start site of MUTYH α.
(b) ChIP using the anti-p53 antibody. The precipitated DNA was analyzed by PCR using primers specific for p21 as a positive control for p53
binding or primers specific for each p53REs. Results from one of two independent experiments are presented. (c) Luciferase reporter assay.
H1299 and HCT116+CHr3 cells were co-transfected with 100 ng of pGL3-promoter vector containing each p53REs and 10 ng of phRL-SV40
vector (left panel). Luciferase activities are shown to represent the fold induction relative to the activity in cells transfected with the pGL3-
promoter luciferase empty vector (pGL3pro), as shown on the left side of each panel. HCT116+Chr3 cells were co-transfected with 200 ng of
pGL3-promoter vector containing either p53RE or mutated p53RE (mutation in p53-binding motif, CTTG→AGGT) and 20 ng of phRL-SV40
vector (right panel). *P= 0.0495 (left panel). *P= 0.0495, **P= 0.0463 (right panel). P-values with Wilcoxon test are shown. Results from three
independent transfection experiments are presented. Mean± s.d.
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pGL3-promoter luciferase reporter without p53RE was used as a
control. As shown in Figure 3c (left panel), the luciferase activity in
H1299 cells was not increased by transfection of the reporter
containing each p53REs. In contrast, the luciferase activity in
HCT116+Chr3 cells transfected with the vector containing p53RE4
or p53RE5 was markedly increased when compared with the
control (Figure 3c, left panel). This transcriptional activation of
luciferase was impaired by mutations of p53RE4 or p53RE5
(Figure 3c, right panel). These results indicate that RE4 and RE5 are
the functional p53RE in the MUTYH genome.
The role of MUTYH as a downstream target of p53 in the oxidative
stress-induced cell death pathway
Next, we examined the influence of p53 deficiency on the
sensitivity to oxidative stress in the human cancer cell lines. The
mismatch repair enzyme, MLH1, has been reported to be involved
in oxidative stress-induced cell death by inhibiting RNA polymer-
ase II-dependent transcription on damaged DNA templates.28 To
exclude the influence of MLH1 deficiency on cell death, we
compared the p53-proficient, MLH1-proficient HCT116+Chr3 cells
and p53-deficient, MLH1-proficient H1299 cells. Cells were
incubated in medium containing various concentrations of
hydrogen peroxide (H2O2) or potassium bromate (KBrO3), a strong
inducer of oxidative stress,29 for 24 h. As a result, p53-proficient
HCT116+Chr3 cells were more sensitive to both H2O2 and KBrO3
than p53-deficient H1299 cells (Figures 4a and b).
To examine whether MUTYH was a downstream mediator of
p53 in cell death, we compared cell viability following suppression
of MUTYH, p53 or both (Figure 5). We first examined the effects of
two different MUTYH-small interfering RNAs (siRNAs) (YsiRNA-2
and YsiRNA-3) separately or together on H2O2-induced cell death
in HCT116+Chr3 cells. The cells transfected with either siRNA
separately or both siRNAs together acquired significant resistance
to cell death induced by H2O2 (Figure 5a, left panel). The
transfection procedure did not affect the cell viability after
exposure to H2O2, as shown by the glyceraldehyde 3-phosphate
dehydrogenase-negative siRNA. The levels of MUTYH mRNA were
effectively reduced 24 h after the transfection (Figure 5a, right
panel). Next, HCT116+Chr3 cells were pretreated for 24 h with
PFTα, a specific p53 inhibitor, and then incubated with PFTα for
24 h in the presence or absence of the two MUTYH-siRNAs. Cells
were then exposed to different concentrations of H2O2 for 24 h.
Cells only exposed to H2O2 without any pretreatment were used
as a control. As shown in Figure 5b, although suppression of
MUTYH or p53 alone increased resistance to H2O2, transfection of
both MUTYH-siRNAs showed no additive effect on viability
following p53 inhibition. We thus conclude that MUTYH is a
potential mediator of p53 in the oxidative stress-induced cell
death pathway. We previously reported that accumulation of 8-
oxoG in nuclear and mtDNA independently triggers two distinct
cell death pathways: one depends on PARP and the other
depends on calpain. Both pathways induce the buildup of SSBs
through MUTYH-initiated base excision repair.14 To clarify which
type of cell death pathway is concerned with the process
mediated by MUTYH, we next examined cell viability in the
presence of the calpain inhibitor MDL28170 or PARP inhibitor
3-aminobenzamide (3-AB) in HCT116+Chr3 cells. As a result, cell
viability was not improved by MDL28170, whereas 3-AB efficiently
increased viability (Figure 5c). We further examined whether PARP
inhibition influences sensitivity to oxidative stress following p53
inhibition in HCT116+Chr3 cells (Figure 5d). As a result, 3-AB had
no additive effect on the viability of cells pretreated with PFTα.
These results suggest that PARP, but not calpains, has a role in
p53-mediated H2O2-induced cell death. Finally, the general pan
caspase inhibitor Z-VAD-fmk did not alter the sensitivity to H2O2,
indicating that caspases are not involved in oxidative stress-
induced cell death in HCT116+Chr3 cells (Figure 5e).
The status of p53 or DNA mismatch repair affects
MUTYH-dependent cell death
Finally, we examined whether the effect of MUTYH-siRNA on
H2O2-induced cell death depends on the status of p53 or DNA
mismatch repair. As shown in Figures 6a and b, MUTYH
knockdown increased cell viability in p53-proficient HCT116
+Chr3, but not in p53-deficient H1299 cells, consistent with the
finding in Figure 5b. Moreover, MUTYH knockdown increased the
viability in MLH1-proficient HCT116+Chr3 cells, but not in MLH1-
deficient HCT116 cells (Figures 6b and c). Similar to other p53-
deficient cell lines, MUTYH knockdown had no effect on the
sensitivity to H2O2 in p53-deficient, MSH6-deficient DLD-1 cells
(Figure 6d). As shown in Figure 6e, MLH1 knockdown in HCT116
+Chr3 cells largely abolished the H2O2 resistance acquired by
MUTYH knockdown. We next confirmed whether MUTYH knock-
down suppressed H2O2-induced cell death in HCT116+Chr3 cells.
As shown in Figure 6f, the percentage of dead cells (12.8%) in
control cell cultures after exposure to 200 μM H2O2 had decreased
to 3.5% in the presence of MUTYH-siRNAs. These results indicate
that both wild-type p53 and MLH1 are required for the induction
of MUTYH-dependent cell death under oxidative stress conditions.
DISCUSSION
Our major conclusions in this study are that human MUTYH is
transcriptionally regulated by p53, and that MUTYH is a potential
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mediator of p53 tumor suppression by inducing death of
premutagenic cells generated under oxidative conditions. More-
over, we propose that PARP is involved in p53-mediated oxidative
stress-induced cell death.
Transcriptional regulation of MUTYH gene expression by p53
In response to a variety of types of DNA damage, p53 regulates a
number of downstream cellular processes such as cell cycle arrest,
apoptosis and DNA repair. In the DNA repair machinery, p53 can
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incubated with 10mM 3-AB for 60min and then exposed to H2O2 for 24 h. (e) Caspase inhibitor does not suppress H2O2-induced cell death.
HCT116+Chr3 cells were pre-incubated with 50 μM Z-VAD-fmk for 60min and then exposed to H2O2 for 24 h. Results shown in panel (b–e) are
from more than four independent experiments. Mean± s.e.m.
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act at several levels that include interaction with APE1 (an AP
endonuclease), DNA polymerase β, enhancement of incision of the
damaged base and possibly transcriptional regulation of OGG1 to
excise 8-oxoG paired with cytosine in DNA.17,30 Moreover, it has
been shown that human MUTYH is transcriptionally regulated by
the p53 family member p73 through a potential binding site
(5′-GCATGGGGCTGATGGAGGCATG-3′) located at − 33 from the
transcriptional start site of MUTYH α mRNA.31 In this study, we
identified two functional p53REs residing within the first intron of
the human MUTYH gene. The p53RE4 (5′-CTTGAGGCCACTTG-3′)
and p53RE5 (5′-CTTGAGAGTGCTTG-3′) located at 5756 and 5829,
respectively (Figure 3a). Real-time RT–PCR analysis revealed that
the levels of MUTYH mRNA were markedly increased following
transfection with the wild-type p53 expression plasmid. Our
findings indicate that MUTYH is a target of transcriptional
regulation by p53. Transcription factor p53 precisely regulates
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Figure 6. The status of p53 or DNA mismatch repair enzyme affects MUTYH-dependent cell death in cancer cell lines. The effect of MUTYH-
siRNA on H2O2-induced cell death in H1299 (a), HCT116+Chr3 (b), HCT116 (c) and DLD-1 cells (d). Control cells were exposed to H2O2 without
transfection. *P= 0.0209, **P= 0.0433. P-values with Wilcoxon test are shown. Results from more than four independent experiments are
presented. Mean± s.e.m. (e) MLH1 knockdown in HCT116+Chr3 cells abolished the H2O2 resistance acquired by MUTYH knockdown (left
panel). HCT116+Chr3 cells were transfected with MUTYH siRNA-2 and 3 (YsiRNAs) or together with MLH1 siRNA (YsiRNAs/MLH1 siRNA).
Twenty-four hours after transfection, cells were incubated in medium containing various concentrations of H2O2 for 24 h. Cells only exposed
to H2O2 without any pretreatment were used as a control. *P= 0.0209 (YsiRNAs vs YsiRNAs/MLH1 siRNA). P-values with Tukey’s HSD test are
shown. Results from four independent experiments are presented. Mean± s.e.m. Expression levels of MLH1 mRNA in HCT116+Chr3 cells
transfected with YsiRNAs or YsiRNAs/MLH1 siRNA (right panel). *P= 0.0013. P-value with Student’s t-test is shown. Results from three
independent transfection experiments are presented. Mean± s.d. (f) Suppression of H2O2-induced cell death by MUTYH-siRNAs. HCT116+Chr3
cells were transfected with MUTYH-siRNA-2 and 3 (YsiRNAs), cultured for 24 h and exposed to H2O2. Percentages of dead cells were
determined 24 h after the exposure. Control cells were exposed to H2O2 without any pretreatment. Control (*P= 0.0304, **P= 0.0294) vs
YsiRNA. P-values with Student’s t-test are shown Mean± s.e.m.
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the OGG1-initiated base excision repair pathway through several
steps. Moreover, the mitochondrial form of MUTYH protein was
not detected by western blot analysis in p53-proficient HCT116
cells, suggesting that the expression of the mitochondrial form of
MUTYH is regulated by a p53-independent mechanism.
PARP, but not calpains, has a role in oxidative stress-induced
p53-mediated cell death
In this study, we found that the PARP inhibitor, but not the calpain
inhibitor, suppresses H2O2-induced cell death in p53-proficient
human colorectal cancer cells. PARP is a molecular nick sensor that
binds specifically to SSBs, and its specific activity involves
catalyzing poly-ADP ribosylation of cellular proteins or of PARP
itself and increasing its enzymatic activity by approximately 500-
fold.32 In addition, apoptosis-inducing factor translocates to the
nucleus in a PARP-dependent manner, and apoptosis-inducing
factor/EndoG-mediated nDNA fragmentation represents a major
mechanism of caspase-independent apoptosis.33,34 Our data
suggest that the PARP-dependent cell death pathway induced
by 8-oxoG accumulation in nDNA is mainly activated in the
p53-proficient colon cancer cell line under oxidative stress
conditions. As shown in Figures 5b and 6b, MUTYH knockdown
rescued 10–20% of cells, and this could be equivalent to the
population of S-phase cells that can generate SSBs through base
excision repair initiated by the nuclear form of MUTYH. In contrast,
the calpain inhibitor did not suppress cell death and the
mitochondrial form of the MUTYH protein was not detected,
suggesting that defects in the cell death pathway induced by
8-oxoG accumulation in mtDNA contribute to decreased sensitiv-
ity to oxidative stress, resulting in tumorigenesis or survival of
cancer cells (Figure 7).
In Figure 6, we found that the effect of MUTYH-siRNA on
H2O2-induced cell death depends on wild-type p53 and MLH1.
The MSH2/MSH6 complex has been reported to be physically
associated with MUTYH at the MSH6-binding site and the
interaction stimulates MUTYH activity.35,36 Kanagaraj et al. recently
showed that depletion of MUTYH suppresses the hypersensitivity
of cells lacking the Werner syndrome helicase/exonuclease and/or
polλ to H2O2.
37 These studies, and our results, provide evidence that
the status of p53 and DNA repair proteins is involved in the
induction of MUTYH-dependent cell death under oxidative stress
conditions.
In addition to MLH1, HCT116 cells are defective in the mismatch
repair enzyme MSH3.38 As the HCT116+Chr3 cell line has been
complemented with an additional chromosome 3 to restore MLH1
gene function, this cell line is still MSH3 deficient. However, a
recent study has reported that MSH3 translocates from the nuclei
to the cytoplasm under oxidative stress conditions, resulting in a
loss-of-function.39 Therefore, it is most likely that H1299 cell also
exhibit MSH3 dysfunction after H2O2 treatment as do HCT116+
Chr3 cells.
MUTYH as a potential mediator of p53 tumor suppression
Several studies indicate that most human cancers show loss of
normal p53 function.40 In response to various stressors, p53 can
induce cell death via a caspase-dependent and -independent
pathway, with the cell death being implicated in suppression of
tumorigenesis.41,42 Recently, it was reported that LL-37, the
human cathelicidin, activates a caspase-independent apoptotic
cascade regulated by p53 that contributes to the suppression
of colon cancer.42 LL-37 activates a GPCR-p53-Bax/Bak/Bcl-2
signaling pathway that triggers apoptosis-inducing factor/
EndoG-mediated apoptosis. We previously demonstrated that
accumulation of 8-oxoG in nDNA and mtDNA independently
triggers two distinct caspase-independent cell death pathways
through MUTYH-initiated base excision repair.14 Thus, p53
deficiency leads to MUTYH dysfunction in stem or progenitor
cells, which results in escape from programmed cell death under
oxidative stress. Accumulated 8-oxoG causes various mutations in
tumor-suppressor genes or proto-oncogenes such as APC or KRAS,
thereby promoting tumorigenesis (Figure 7).
The p53-mediated cell death pathway is also known to be
involved in the development of neurodegenerative diseases.43
Increased p53 immunoreactivity was observed in sporadic
Alzheimer's disease, especially in sub-populations of cortical
neurons undergoing neurofibrillary degeneration.44 The amyloid
β-42 peptide, which has a pivotal role in Alzheimer's disease, binds
to the p53 promoter and enhances transcription, resulting in
apoptosis of primary human neurons.45 Oxidative stress is
considered to be important in the etiology of several neurode-
generative disorders.46 We recently reported that 8-oxoG accu-
mulation in nDNA or mtDNA causes neurodegeneration during
MUTYH-mediated DNA base excision repair.47 Moreover, increased
MUTYH expression was observed in the mitochondria of
substantia nigra neurons in Parkinson’s disease patients.48 These
findings suggest that enhancement of MUTYH expression by p53
can lead to neuronal loss under oxidative stress conditions.
In conclusion, we propose that MUTYH can be an effective
mediator for anticancer therapies. Radiation or anticancer drugs
are known to produce ROS resulting in increased accumulation of
8-oxoG in cellular DNA, thereby MUTYH-dependent cell death
could effectively eliminate cancer cells. To minimize the side
effects of anticancer therapies, MUTYH inhibitors selectively
delivered to normal tissue would be beneficial. Thus, we
emphasize that the identification of p53 status and DNA repair
proteins including MUTYH is important for the accurate assess-
ment and treatment of cancer.
MATERIALS AND METHODS
Cell lines
The H1299 non-small cell lung carcinoma cell line21 and HeLa MR and
HeLaS325 human cervical carcinoma cell lines were laboratory stocks. The
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Figure 7. MUTYH mediates p53 tumor suppression via PARP/MLH1-
dependent cell death. p53 deficiency leads to MUTYH dysfunction in
stem or progenitor cells, which results in escape from programmed
cell death under oxidative stress. Accumulated 8-oxoG causes
various mutations in tumor-suppressor genes or proto-oncogenes,
thereby promoting tumorigenesis. Loss of the mitochondrial form
MUTYH in p53-proficient cells also induces carcinogenesis via
escape from cell death.
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HCT116 colon adenocarcinoma cell line was purchased from ATCC
(Manassas, VA, USA). The human colon cancer cell lines, DLD-1 and
HT29,26 were a gift from Dr S Oda (National Kyushu Cancer Center,
Fukuoka, Japan). The HCT116+Chr3 cell line22 was a gift from Dr CR Boland
(Baylor University Medical Center, Dallas, TX, USA). Cells were cultured in
Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad, CA, USA)
supplemented with 10% (v/v) heat-inactivated fetal bovine serum, 100 μg/
ml streptomycin and 100 units/ml penicillin, at 37 °C in 5% (v/v) CO2.
Real-time quantitative RT–PCR analysis
Total RNA was extracted using ISOGEN (Nippon Gene, Tokyo, Japan). Two
micrograms each of RNA sample was reverse-transcribed using the High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City,
CA, USA) and random hexamer primers. Real-time quantitative RT–PCR was
performed on an ABI 7500 machine (Applied Biosystems). Each reaction
was performed with the appropriate amount of complementary DNA,
optimized amount of forward and reverse primers and 12.5 μl 2 × Power
SYBR Green Master Mix (Applied Biosystems) in a total volume of 25 μl. The
primers used for PCR were as follows: MUTYH α-specific primers (forward,
5′-GAGGAGCCTCTAGAACTATGA-3′; reverse, 5′-CTTGGCCTGACTGTTGTTCT-3′),
MUTYH β-specific primers (forward, 5′-CTCCGTGTTCTGCTGTCTTC-3′;
reverse, 5′-CTTGGCCTGACTGTTGTTCT-3′), p21-specific primers (forward,
5′-TGGAGACTCTCAGGGTCGAAA-3′; reverse, 5′-GGCGTTTGGAGTGGTAGAA
ATC-3′), 18S ribosomal RNA-specific primers (forward, 5′-CTTAGAGGG
ACAAGTGGCG-3′; reverse, 5′-GGACATCTAAGGGCATCACA-3′) and MLH1-
specific primers (forward, 5′-TGGGACGAAGAAAAGGAATG-3′; reverse,
5′-TCCAGGAGTTTGGAATGGAG-3′).
Plasmids, transfection and luciferase reporter assay
The pCMV-p53 vector that encodes wild-type p53 and the pCMV-
p53mt135 vector that encodes dominant-negative p53 (C135Y)49 were
purchased from Clontech Laboratories Inc. (Mountain View, CA, USA). Cells
were transfected with the pCMV-p53 vector using Effectene (Qiagen,
Germantown, MD, USA) and subjected to real-time quantitative RT–PCR
24 h after transfection. To inactivate endogenous p53 in HCT116 cells, cells
were transfected with the pCMV-p53mt135 vector using Effectene and
selected with 400 ng/μl G418 (Invitrogen) for 72 h after transfection. After
24-h culture, cells were subjected to real-time quantitative RT–PCR and
western blot analysis.
Plasmids for the luciferase reporter assay were created using the pGL3-
promoter vector (Promega, Madison, WI, USA). Synthetic oligonucleotides
containing p53RE or mutated p53RE (mutation in p53-binding motif,
CTTG→AGGT) were cloned to the SacI and XmaI sites of the pGL3-
promoter vector. All clones were sequenced to rule out any mutations.
For luciferase assay, cells were cultured in 24-well plates and each well was
co-transfected with the pGL3-promoter vector containing the p53RE and
pRL-SV40 plasmid encoding Renilla luciferase (Promega). The luciferase
activity was measured using the Dual-Gro Luciferase Reporter Assay
system (Promega) 48 h after transfection. The transfection efficiency was
determined by the Renilla luciferase activity.
Western blot analysis and Immunostaining
Anti-HCD against the highly conserved domain of hOGG1 isoforms has
been described.50 Anti-MUTYH rabbit polyclonal antibodies were used
as described previously.24 Antibodies against PCNA (PC10; Abcam,
Cambridge, MA, USA), HSP60 (LK-1; StressGen, San Diego, CA, USA) were
also used. For immunostaining, digital images were separately captured
from identical fields using an LSM-510 Meta confocal microscopy system
(Carl Zeiss, Jena, Germany). Images were processed for publication by
Adobe Photoshop CS5 software (Adobe System Inc., San Jose, CA, USA).
Chromatin immunoprecipitation
ChIP assays were performed using the EZ ChIP (Millipore, Billerica, MA,
USA) according to the manufacturer's protocol with some modifications.
Briefly, 4 × 106 cells per immunoprecipitation were cross-linked with 37%
(v/v) formaldehyde and sonicated to produce chromatin fragments
between 500 and 1000 bp. Chromatin was subsequently incubated with
anti-p53 antibody (Ab-1; Oncogene Science, Cambridge, MA, USA)
overnight at 4 °C. Immunoprecipitated samples were treated as described
by the manufacturer's instructions, and purified DNA from the ChIP
samples was assayed by PCR. The primers used for PCR were as follows:
p21 (forward, 5′-CATCCCCACAGCAGAGGAGAA-3′; reverse, 5′-ACCCAGGC
TTGGAGCAGCTA-3′), p53RE1 (forward, 5′-TGTAGGGCTTGAGGATCTCA-3′;
reverse, 5′-GAAGGTAGGACGTATTGGGA-3′), p53RE2/3 (forward, 5′-GGG
GTGGAAGGATCAGAGAG-3′; reverse, 5′-CCAAAAAAATTAGCCAGACG-3′)
and p53RE4/5 (forward, 5′-TCTTTGCATGTCTCCAGGGC-3′; reverse, 5′-CCC
TCTCATCCACCATTCAC-3′).
Cell viability and cell death assay
Cell viability was determined using the 2-(2-methoxy-4-nitrophenyl)-3-
(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt
(WST-8) assay and the Cell Counting Kit-8 (Wako Pure Chemical Industries,
Osaka, Japan). In brief, cells were cultured in 96-well plates to ~ 70%
confluence using MEM (Invitrogen) supplemented with 10% (v/v) heat-
inactivated fetal bovine serum, 100 μg/ml streptomycin and 100 units/ml
penicillin and incubated with medium containing various concentrations
of H2O2 or KBrO3, followed by incubation with WST-8. Absorbance of
WST-8 formazan dye at 450 nm was measured, and relative cell viability
was determined as a percentage of the absorbance of cells without
exposure. MDL28170 from BIOMOL (Phymouth Meeting, PA, USA); PFTα,
3-AB was obtained from Sigma-Aldrich (St Louis, MO, USA). To determine
the percentage of dead cells, the number of dead cells stained with both
Hoechst33342 and propidium iodide was divided by the total number of
cells stained with Hoechst.
siRNA and transfections
Two human MUTYH-siRNAs (YsiRNA-2, s9091; YsiRNA-3, s9092) and
glyceraldehyde 3-phosphate dehydrogenase-negative siRNA (4603G) as a
negative control were purchased from Ambion (Austin, TX, USA). Human
MLH1 siRNA (Silencer MLH1 siRNA; 119549) was purchased from Applied
Biosystems. Cells were transfected with each siRNA using a siPORT lipid,
Silencer TM siRNA Transfection Kit (Ambion).
Statistical analysis
All statistical analyses were carried out using JMP 8.01 software (SAS
Institute, Cary, NC, USA).
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